Racial Differences Among High-Risk Patients Presenting With Non–ST-Segment Elevation Acute Coronary Syndromes (Results from the SYNERGY Trial)††Disclosure: Drs. Mahaffey, Cohen, Newby, Ferguson, and Califf have received honoria for speaking from sanofi-aventis. Drs. Mahaffey, Ferguson, and Califf have acted as consultants for sanofi-aventis. Drs. Echols, Velazquez, Santos, and Gurfinkel have no financial relationships to disclose.
Melvin Echols(Durham University), Robert M. Califf(Duke University), Karen S. Pieper(Clinical Research Institute), Renato M. Santos(Wake Forest University), Luigi M. Biasucci(Agostino Gemelli University Polyclinic), Eric J. Velazquez(Yale University), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Alexandra J. Lansky(Queen Mary University of London), L. Kristin Newby(Duke University), Anindita Banerjee(Pfizer (United States)), Enrique Gurfinkel(Favaloro Foundation), Amanda Stebbins(University of Alberta), James J. Ferguson(Brigham and Women's Hospital), Mauricio G. Cohen(Santa Ana College)
Cited by 21
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k